RT期刊文章SR电子T1基础体温:矛盾与严重程度和Non-Modification研究所TPA治疗获益的中风试验(P3.101)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P3.101 VO 82是10补充A1 Seo Kim Hyun A1 Jeffrey节省年2014 UL //www.ez-admanager.com/首页content/82/10_Supplement/P3.101.abstract AB目的:研究的目的是调查的影响基础体温(BT)组织纤溶酶原激活物(TPA)受益。背景:虽然上升BT在卒中后第一个24小时内增加中风的严重程度和更糟糕的结果,一些研究发现BT实际上更低,严重影响患者起初表示,可能修改影响溶栓治疗。方法:我们分析了公共数据集的两个NINDS-TPA中风试验,比较患者较低(< 37.0°),高(蠅37.0°)BT。结果:在招收了595名患者记录初始BT, 77.1%(226安慰剂和229 tPA)基线BT < 37.0°和22.9%安慰剂(71和69 tPA) BT蠅37.0°。BT较高的患者低基线中风严重性两tPA患者(署值,11和15;p = 0.046)和安慰剂的患者(平均13和16个;p = 0.004)。患者高BT也低两tPA梗死体积CT在3个月(平均9.6 vs 16.7立方厘米;p = 0.078)和安慰剂(中位数,13.1 vs 28.1立方厘米;p = 0.019)。与调整为13基线变量回归分析预测的结果,tPA是同样有效的高和低BT组(蠅37.0°:夫人或0 - 1的结果2.55,95%可信区间1.05 - -6.21; <37.0°: OR 2.30, 95% CI 1.38-3.84; p = 0.831). CONCLUSIONS: In hyperacute stroke patients, higher presenting temperatures are associated with less severe stroke deficits and final infarct volumes. Presenting temperature does not modify the benefit of tPA on good functional outcome at 3 months.Disclosure: Dr. Kim has nothing to disclose. Dr. Saver has received personal compensation for activities with the University of California, BrainsGate, CoAxia, ev3, Talecris, PhotoThera, Sygnis, and Stryker. Dr. Saver has received research support from the University of California, and the National Institutes of Health.Tuesday, April 29 2014, 3:00 pm-6:30 pm